Pharma BD Deal Intelligence
A $460M bolt-on that quietly became part of the foundation for Lonza's multi-billion-dollar CDMO/biologics juggernaut
Full analysis, sources & comparables →Cambrex announced $460M cash sale of bio businesses; net proceeds ~$450M to repay debt and fund a $13.50–$14.50/share special dividend, refocusing on Human…
Deal closed February 2007 (announced Oct 2006); Lonza emerged as a top-tier global biologics CDMO with significantly expanded mammalian and microbial capacity.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Lonza acquired Cambrex's Bioproducts and Biopharma businesses for $460 million in cash, the largest acquisition in Lonza's history at the time, consolidating its position as a leading biopharmaceutical CDMO. Cambrex used the roughly $450 million net proceeds to repay debt and fund a special dividend while refocusing on its human-health small-molecule API business; the deal closed in February 2007.
A $460M bolt-on that quietly became part of the foundation for Lonza's multi-billion-dollar CDMO/biologics juggernaut
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses (this deal) | 2006 | $460M | 83 |
| Lonza Group AG / Capsugel S.A. | 2016 | $5.5B | 44 |
| Lonza Group AG / Capsugel S.A. (KKR portfolio) | 2016 | $5.5B | 39 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals · Lonza Group AG deals